Related Experiment Video
Updated: Aug 7, 2026
Optimizing Isolation and Purification of Murine Glomerular Mesangial Cells
Published on: March 7, 2025
Honokiol, a small molecular weight natural product, alleviates experimental mesangial proliferative
C-K Chiang1, M-L Sheu, K-Y Hung
1Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Insights
Honokiol, an anti-inflammatory compound, reduced urinary protein and improved kidney health in rats with glomerulonephritis (GN). This suggests honokiol may be a potential treatment for mesangial proliferative GN, a common cause of kidney failure.
Area of Science:
- Nephrology
- Pharmacology
- Immunology
Background:
- Glomerulonephritis (GN) is a leading cause of end-stage renal disease.
- Key features of GN include glomerular macrophage accumulation, mesangial cell proliferation, and extracellular matrix deposition.
- Targeting these pathological processes may slow GN progression.
Purpose of the Study:
- To investigate the therapeutic potential of honokiol in a rat model of anti-Thy1 nephritis.
- To evaluate honokiol's effects on key pathological markers and urinary protein excretion in GN.
Main Methods:
- Anti-Thy1 nephritis was induced in Wistar rats.
- Rats received honokiol or vehicle, and outcomes were assessed via histological analysis, immunohistopathology, and urine protein measurements.
- Gene expression of adhesion molecules, chemokines, and extracellular matrix proteins was analyzed using Northern blotting.
Main Results:
- Honokiol treatment significantly reduced urinary protein excretion, glomerular cellularity, and sclerosis in nephritic rats.
- Honokiol abolished the increase in proliferating cell nuclear antigen and Akt phosphorylation.
- Honokiol alleviated the expression of monocyte chemoattractant protein-1, intracellular adhesion molecule-1, type I collagen, and fibronectin mRNA.
Conclusions:
- Honokiol demonstrates therapeutic potential for mesangial proliferative glomerulonephritis.
- Its anti-inflammatory and anti-proliferative effects may mitigate key pathological features of GN.
Abstract:
Glomerulonephritis (GN) is still the most common cause of end-stage renal disease. Accumulation of glomerular macrophages, proliferation of mesangial cells, and deposition of extracellular matrix proteins are pathobiological hallmarks of GN. Pharmacological interventions that can inhibit these insults may be beneficial in the retardation of the progression of GN. Honokiol originally isolated from Magnolia officinalis, shows antioxidative, anti-inflammatory, and antiproliferative activities in a variety of inflammation models. In this study, we first investigated the in vivo effects of honokiol on rat anti-Thy1 nephritis. Anti-Thy1 nephritis was induced in Wistar rats by injecting mouse anti-rat Thy1 antibodies intravenously. Nephritic rats were randomly assigned to receive honokiol (2.5 mg/kg, twice a day) or vehicle and were killed at various time points. Glomerular histology and immunohistopathology and urine protein excretion were studied. Western blotting was conducted for markers of proliferation. Adhesion molecules, chemokine, and extracellular matrix gene expression were evaluated by Northern blotting. Honokiol-treated nephritic rats excreted less urinary protein and had lower glomerular cellularity and sclerosis. The increased intraglomerular proliferating cell nuclear antigen and Akt phosphorylation in nephritic rats could be abolished by the treatment of honokiol. Honokiol also alleviated glomerular monocyte chemoattractant protein-1 and intracellular adhesion molecule-1, similar to type I (alpha1) collagen and fibronectin mRNA levels of nephritic rats. These results indicate that honokiol may have therapeutic potential in mesangial proliferative GN.
